CORE-DBS: Registry Study on Deep Brain Stimulation at the University Hospital Cologne

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038684

Enrollment

900

Registered

2025-12-09

Start date

2024-03-01

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: Deep brain stimulation (DBS) is an established therapeutic approach for advanced movement disorders such as Parkinson’s disease, essential tremor, and dystonia. Beyond randomized controlled t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults (= 18 years) presented at the University Hospital Cologne for evaluation of treatment with an implanted stimulation system. Adults who have already received such a stimulation system and are followed up at the same center. Ability to understand the study and provide informed consent. Written informed consent.

Exclusion criteria

Exclusion criteria: Lack of capacity to provide informed consent. No written informed consent. Withdrawal of consent at any time.

Design outcomes

Primary

Measure	Time frame
All listed data are obtained as part of routine clinical care, without study-specific examinations or additional visits. The evaluations take place at the pre-surgical indication assessment and at three, six, twelve, and twenty-four months postoperatively. Age; Sex; Weight; Height; Primary diagnosis; Diagnosis date; Date of first symptom onset; Relevant comorbidities; Assessment timepoint (pre-surgical evaluation/surgery/follow-up); Date of surgery; Anatomical target; Neuromodulation system (manufacturer/type); Stimulation parameters (contact selection; amplitude; frequency; pulse width; limits); Medication plan; Clinical scales (Parkinson: Hoehn–Yahr; MDS-UPDRS; Marconi; MDS-NMSS; PDQ-39; FOG-Q; C-FOG; VHI; DBS-IS; PD-StigmaQuest; MMSE; FLW; PANDA; MoCA; HADS-D; AES; MSS; QUIPS-RS; BDI-II; Fatigue scale; Essential tremor: TETRAS; TRS-A/B/C; QUEST; ADL; VHI; VAS tremor/gait/speech; CCAS; Dystonia: TRS-B; SF-36; VHI; RUI); Surgical report; Electrophysiology (beta survey; sensing); Pre/post-operative imaging (MRI; CT); if available nuclear imaging (FDG-PET; DaT-SPECT); Speech recording; Video recording; Study withdrawal (date; reason).	—

Measure

Time frame

All listed data are obtained as part of routine clinical care, without study-specific examinations or additional visits. The evaluations take place at the pre-surgical indication assessment and at three, six, twelve, and twenty-four months postoperatively. Age; Sex; Weight; Height; Primary diagnosis; Diagnosis date; Date of first symptom onset; Relevant comorbidities; Assessment timepoint (pre-surgical evaluation/surgery/follow-up); Date of surgery; Anatomical target; Neuromodulation system (manufacturer/type); Stimulation parameters (contact selection; amplitude; frequency; pulse width; limits); Medication plan; Clinical scales (Parkinson: Hoehn–Yahr; MDS-UPDRS; Marconi; MDS-NMSS; PDQ-39; FOG-Q; C-FOG; VHI; DBS-IS; PD-StigmaQuest; MMSE; FLW; PANDA; MoCA; HADS-D; AES; MSS; QUIPS-RS; BDI-II; Fatigue scale; Essential tremor: TETRAS; TRS-A/B/C; QUEST; ADL; VHI; VAS tremor/gait/speech; CCAS; Dystonia: TRS-B; SF-36; VHI; RUI); Surgical report; Electrophysiology (beta survey; sensing); Pre/post-operative imaging (MRI; CT); if available nuclear imaging (FDG-PET; DaT-SPECT); Speech recording; Video recording; Study withdrawal (date; reason).

—

Countries

Germany

Contacts

Public ContactMichael T. Barbe

Universitätsklinikum Köln

michael.barbe@uk-koeln.de0221/478 7494

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026